Clinical Trial Update: Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing pharmacokinetics and safety of givinostat in children with Duchenne muscular dystrophy aged 2 to under 6 years.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Givinostat (givinostat)

Snippet

Sponsor: Italfarmaco | Conditions: Duchenne Muscular Dystrophy | Phase 2 | Status: RECRUITING